{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-089340","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.914438+00:00","generated_at":"2026-05-31T09:16:55.345273+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sagimet Q2 net loss $8.1M, cash $188.5M; denifanstat fibrosis data positive; Phase 3 plan H2 2024","bullets":["Cash and marketable securities $188.5M as of June 30, 2024; net loss $8.1M for Q2 2024 vs $6.8M year ago.","Denifanstat Phase 2b: fibrosis improvement ≥1 stage in 30% vs 14% placebo (ITT); 49% vs 13% in F3 patients.","Anne Phillips and Jennifer Jarrett appointed to board effective August 1, 2024.","Phase 3 program for denifanstat in MASH expected to start H2 2024; CRO contract executed.","R&D expense $6.3M and G&A $4.3M in Q2 2024, up from $4.7M and $2.4M year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-089340","json":"https://secwatch.observer/filing/0001104659-24-089340.json","markdown":"https://secwatch.observer/filing/0001104659-24-089340.md","text":"https://secwatch.observer/filing/0001104659-24-089340.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924089340/0001104659-24-089340-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924089340/tm2421625d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:16:55.345273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}